CMS Open Payments · Program Year 2024
Biodermis LLC
Biodermis LLC reported $12,500.00 across General Payments, Research, and Ownership to 2 physicians and teaching hospitals across 2 transactions.
- $12.5K Below-median payer
- All-tracks total
- 2 Below-median volume
- Transactions
- 2 Below-median reach
- Recipients
- #1609
- of 1,925 companies
Biodermis LLC reported $12,500.00 across all CMS Open Payments tracks (General + Research + Ownership) to 2 physicians and teaching hospitals in Program Year 2024 - ranking #1609 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $12,500.00, averaging $6.3K per recipient.
Biodermis LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
10/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer biodermis-llc Biodermis LLC
$12.5K · #1609/1,925 · 0.0% industry · PY2024
- TOT $12.5K
- RANK #1609
- SHARE 0.0%
- TXN 2
- RCP 2
- CAT 1
- GEN $12.5K
- TOP1 100.0%
- PY 2024
Volume peers
Nearest volume peer: IMPLANET America, Inc. ($12.6K)
Biodermis LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Biodermis LLC
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Biodermis LLC that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
Of the 1 general-payment categories charted below, "Compensation for Faculty or Speaker (Medical Education)" is the largest at $12.5K across 2 transactions, 100.0% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Biodermis LLC made 1 types of general payments. "Compensation for Faculty or Speaker (Medical Education)" is the largest category at $12.5K, 100.0% of General Payments.
How Biodermis LLC divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Faculty or Speaker (Medical Education) | $12.5K | 2 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $12,500.00 (100.0%) of $12,500.00 in this company's General Payments records across 1 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Biodermis LLC
The five named recipients with the highest reported General Payments from this company
- 1
Raffi Hovsepian
$12,500.00 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Biodermis LLC ranks #1609 of 1,925 by total payments (bottom 16% by spend) but is notably more concentrated than that alone would suggest -- #130 of 1,838 by HHI (top 7% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Ziemek Dental Laboratory, Inc. : $61.9K total payments, HHI 10000
- Archimmune Therapeutics Inc. : $897.86 total payments, HHI 10000
- Clarix Imaging Corporation : $3.7K total payments, HHI 10000
- Sentrimed, Inc. : $4.0K total payments, HHI 10000
- Nurami Medical Inc : $1.5K total payments, HHI 10000
- Fluoptics Sas : $7.5K total payments, HHI 10000
- Biodermis LLC (this company) : $12.5K total payments, HHI 10000
- Angelus Industria de Produtos Odontologicos S.A. : $250.00 total payments, HHI 10000
- Covalon Technologies (USA) Ltd. : $12.6K total payments, HHI 10000
- DermaSensor Inc : $39.94 total payments, HHI 10000
- Lumos Diagnostics, Inc. : $3.9K total payments, HHI 10000
- FKG Dentaire Sarl : $56.8K total payments, HHI 10000
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Biodermis LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Biodermis LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Biodermis LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Cytyc Surgical Products, LLC
Sentec, Inc.
Validus Pharmaceuticals LLC
Smaio USA Corporation
Corbin Clinical Resources
Put this to use
Biodermis LLC ranks #1609 of 1,925 by all-tracks total payments, led by "Compensation for Faculty or Speaker (Medical Education)".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Compensation for Faculty or Speaker (Medical Education)" spend across every manufacturer, not just Biodermis LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.